Seikagaku Corporation

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Seikagaku Corporation sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 12 completed top decile by trial count

Seikagaku Corporation: 12 sponsored US clinical trials, none currently recruiting.

Seikagaku Corporation sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 6 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Syndromes, with 2 trials.

Top-decile sponsor footprint

Seikagaku Corporation ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 3

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

NCT05411367
COMPLETED Phase 1

PK and Safety of SI-722 in IC/BPS

NCT04208087
COMPLETED Phase 3

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

NCT03607838
COMPLETED Phase 2

SI-613 Study for Knee Osteoarthritis

NCT03209362
COMPLETED Phase 3

A Study of SI-6603 in Patients With Lumbar Disc Herniation

NCT02421601
COMPLETED Phase 2

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

NCT02205840
COMPLETED Phase 3

A Study of SI-6603 in Patients With Lumbar Disc Herniation

NCT01941563
COMPLETED NA

Gel-One Treatment in Knee Osteoarthritis

NCT01934218
COMPLETED Phase 2

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

NCT01558999
COMPLETED Phase 2

Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

NCT01282606
COMPLETED Phase 3

Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee

NCT00450112
COMPLETED Phase 3

Gel-200 Versus Placebo in Osteoarthritis of the Knee

NCT00449696

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 6

Therapeutic Areas

Dry Eye Syndromes 2
Dry Eye Disease 1

How the Seikagaku Corporation archive is shaped

12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).

Phase mix: 6 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Dry Eye Syndromes (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Seikagaku Corporation: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Seikagaku Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Seikagaku CorporationAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Seikagaku Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Seikagaku Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Seikagaku Corporation page

12 registered trials is a research-attention snapshot, not an endorsement of Seikagaku Corporation or any single study.

  • None of Seikagaku Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dry Eye Syndromes is the condition Seikagaku Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Syndromes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Seikagaku Corporation pipeline card: 12 registered trials from official public datasets.Report a data error.